Establishment of the Cancer Prevention Study II Nutrition Cohort Colorectal Tissue Repository

Campbell, Peter T.; Deka, Anusila; Briggs, Peter; Cicek, Mine S.; Farris, Alton B.; Gaudet, Mia M.; Jacobs, Eric J.; Newton, Christina C.; Patel, Alpa V.; Teras, Lauren R.; Thibodeau, Stephen N.; Tillmans, Lori S.; Gapstur, Susan M.

doi:10.1158/1055-9965.epi-14-0541

Cited by 23 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This rate compares favorably with the rate reported for the Cancer Prevention Study II Nutrition Cohort Colorectal Tissue Repository (43%) (12). The CPS II effort also reported a higher success rate (87%) for cases diagnosed within 10 years of the collection date than those diagnosed more than 10 years (32%).…”

Section: Discussionsupporting

confidence: 72%

The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource

Zhu

Huang

Pinsky

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background Pathology tissue specimens with associated epidemiological and clinical data are valuable for cancer research. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial undertook a large-scale effort to create a public resource of pathology tissues from PLCO participants who developed a cancer during the trial. Methods Formalin-Fixed Paraffin-Embedded (FFPE) tissue blocks were obtained from pathology laboratories on a loan basis for central processing of tissue microarrays, with additional free-standing tissue cores collected for nucleic acid extraction. Results Pathology tissue specimens have been obtained for prostate cancer (n=1,052), lung cancer (n=434), colorectal cancer (n=675) and adenoma (n=658), ovarian cancer and borderline tumors (n=212), breast cancer (n=870) and bladder cancer (n=204). The process of creating this resource was complex, involving multi-disciplinary teams with expertise in pathology, epidemiology, information technology, project management and specialized laboratories. Conclusions Creating the PLCO tissue resource required a multi-step process including obtaining medical records and contacting pathology departments where pathology materials were stored after obtaining necessary patient consent and authorization. The potential to link tissue biomarkers to prospectively collected epidemiological information, screening and clinical data, and matched blood or buccal samples offers valuable opportunities to study etiologic heterogeneity, mechanisms of carcinogenesis and biomarkers for early detection and prognosis. Impact The methods and protocols developed for this effort, and the detailed description of this resource provided here will be useful for those seeking to use PLCO pathology tissue specimens for their research and may also inform future tissue collection efforts in other settings.

show abstract

Section: Discussionsupporting

confidence: 72%

The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource

Zhu

Huang

Pinsky

et al. 2016

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Immigration epidemiological studies have reported that after the residents in low-incidence countries moved to high-incidence regions, the morbidity of colorectal cancer increased rapidly [37], which primarily attributed to the changes of dietary habit and lifestyle [38]. Tea, as one of the most popular beverages consumed worldwide, has been widely investigated the effects on human health.…”

Section: Discussionmentioning

confidence: 99%

An inverse association between tea consumption and colorectal cancer risk

Chen

et al. 2017

Oncotarget

View full text Add to dashboard Cite

It is well known that the tea extracts, mainly polyphenols as chemo-preventive elements, could act as cancer progression blockers. Although the association between tea consumption and colorectal cancer risk has been widely investigated, the results still remain inconsistent. We conducted a dose-response meta-analysis to evaluate their relationships by enrolling qualified 29 literatures. The summary odds ratio (OR) of colorectal cancer for the highest vs. lowest tea consumption was 0.93 with 0.87–1.00 of 95% confidence intervals (CIs) among all studies with modest heterogeneity (P = 0.001, I2 = 43.4%). Stratified analysis revealed that tea, especially green tea, had a protective effect among female and rectal cancer patients. Particularly, the dose-response analysis showed that there was a significant inverse association between an increment of 1 cup/day of tea consumption and colorectal cancer risk in the subgroup of the green tea drinking (OR = 0.98, 95% CI = 0.96–1.01, Pnonlinear = 0.003) and female (OR = 0.68, 95% CI = 0.56-0.81, Pnonlinear < 0.001). Our findings indicate that tea consumption has an inverse impact on colorectal cancer risk, which may have significant public health implications in the prevention of colorectal cancer and further similar researches.

show abstract

“…Third, we collected detailed information on potential confounders and had a high follow-up rate of the cohorts. Fourth, this study represents a unique integrative molecular pathological epidemiology [47-52] analysis of prediagnostic plasma vitamin D and immunity status in tumour tissue, which has enabled us to provide novel epidemiologic evidence on the potential role of vitamin D in cancer immunoprevention.…”

Section: Discussionmentioning

confidence: 99%

Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status

Song

Nishihara

Wang

et al. 2015

Gut

View full text Add to dashboard Cite

Objective Evidence suggests protective effects of vitamin D and anti-tumour immunity on colorectal cancer risk. Immune cells in tumour microenvironment can convert 25-hydroxyvitamin D [25(OH)D] to bioactive 1α,25-dihydroxyvitamin D3, which influences neoplastic and immune cells as an autocrine and paracrine factor. Thus, we hypothesised that the inverse association between vitamin D and colorectal cancer risk might be stronger for cancers with high-level immune response than those with low-level immune response. Design We designed a nested case-control study (318 rectal and colon carcinoma cases and 624 matched controls) within the Nurses’ Health Study and Health Professionals Follow-up Study, using molecular pathological epidemiology database. Multivariable conditional logistic regression was used to assess the association of plasma 25(OH)D with tumour subtypes according to the degree of lymphocytic reaction, tumour-infiltrating T-cells (CD3+, CD8+, CD45RO+ and FOXP3+ cells), microsatellite instability, or CpG island methylator phenotype. Results The association of plasma 25(OH)D with colorectal carcinoma differed by the degree of intratumoural periglandular reaction (Pheterogeneity=0.001); high 25(OH)D was associated with lower risk of tumour with high-level reaction [comparing the highest vs. lowest tertile: odds ratio, 0.10; 95% confidence interval, 0.03 to 0.35; Ptrend<0.001], but not risk of tumour with lower-level reaction (Ptrend>0.50). A statistically non-significant difference was observed for the associations of 25(OH)D with tumour subtypes according to CD3+ T-cell density (Pheterogeneity=0.03; adjusted statistical significance level of α=0.006). Conclusion High plasma 25(OH)D level is associated with lower risk of colorectal cancer with intense immune reaction, supporting a role of vitamin D in cancer immunoprevention through tumour-host interaction.

show abstract

Establishment of the Cancer Prevention Study II Nutrition Cohort Colorectal Tissue Repository

Cited by 23 publications

References 26 publications

The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource

The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource

An inverse association between tea consumption and colorectal cancer risk

Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status

Contact Info

Product

Resources

About